Hepatopulmonary syndrome

David G. Koch; Michael B. Fallon

doi:10.1097/MOG.0000000000000067

Hepatopulmonary syndrome

David G. Koch, Michael B. Fallon

Internal Medicine, Phoenix

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Purpose of Review To discuss the advances in the understanding of the pathophysiology of experimental and human hepatopulmonary syndrome (HPS) and in the management of HPS, particularly regarding liver transplantation. Recent Findings Advances have been made in defining the pathophysiology of HPS in experimental models as well as in human disease, including the role of endothelin-1, pulmonary monocytes, and angiogenesis. Additionally, the implications of the presence of HPS as it relates to prioritizing patients for liver transplantation and posttransplant outcomes will also be reviewed. Summary: Mechanisms of disease continue to be defined in HPS, providing potential targets for pharmacologic intervention. Outcomes after liver transplantation are also becoming clearer, including the management of HPS with severe hypoxemia.

Original language	English (US)
Pages (from-to)	260-264
Number of pages	5
Journal	Current Opinion in Gastroenterology
Volume	30
Issue number	3
DOIs	https://doi.org/10.1097/MOG.0000000000000067
State	Published - May 2014

Keywords

hepatopulmonary syndrome
hypoxemia
intrapulmonary vasodilatation
liver transplantation
portal hypertension

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1097/MOG.0000000000000067

Cite this

@article{d8263a0ed6ca4570aa91096b686ed6db,

title = "Hepatopulmonary syndrome",

abstract = "Purpose of Review To discuss the advances in the understanding of the pathophysiology of experimental and human hepatopulmonary syndrome (HPS) and in the management of HPS, particularly regarding liver transplantation. Recent Findings Advances have been made in defining the pathophysiology of HPS in experimental models as well as in human disease, including the role of endothelin-1, pulmonary monocytes, and angiogenesis. Additionally, the implications of the presence of HPS as it relates to prioritizing patients for liver transplantation and posttransplant outcomes will also be reviewed. Summary: Mechanisms of disease continue to be defined in HPS, providing potential targets for pharmacologic intervention. Outcomes after liver transplantation are also becoming clearer, including the management of HPS with severe hypoxemia.",

keywords = "hepatopulmonary syndrome, hypoxemia, intrapulmonary vasodilatation, liver transplantation, portal hypertension",

author = "Koch, {David G.} and Fallon, {Michael B.}",

year = "2014",

month = may,

doi = "10.1097/MOG.0000000000000067",

language = "English (US)",

volume = "30",

pages = "260--264",

journal = "Current Opinion in Gastroenterology",

issn = "0267-1379",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Hepatopulmonary syndrome

AU - Koch, David G.

AU - Fallon, Michael B.

PY - 2014/5

Y1 - 2014/5

N2 - Purpose of Review To discuss the advances in the understanding of the pathophysiology of experimental and human hepatopulmonary syndrome (HPS) and in the management of HPS, particularly regarding liver transplantation. Recent Findings Advances have been made in defining the pathophysiology of HPS in experimental models as well as in human disease, including the role of endothelin-1, pulmonary monocytes, and angiogenesis. Additionally, the implications of the presence of HPS as it relates to prioritizing patients for liver transplantation and posttransplant outcomes will also be reviewed. Summary: Mechanisms of disease continue to be defined in HPS, providing potential targets for pharmacologic intervention. Outcomes after liver transplantation are also becoming clearer, including the management of HPS with severe hypoxemia.

AB - Purpose of Review To discuss the advances in the understanding of the pathophysiology of experimental and human hepatopulmonary syndrome (HPS) and in the management of HPS, particularly regarding liver transplantation. Recent Findings Advances have been made in defining the pathophysiology of HPS in experimental models as well as in human disease, including the role of endothelin-1, pulmonary monocytes, and angiogenesis. Additionally, the implications of the presence of HPS as it relates to prioritizing patients for liver transplantation and posttransplant outcomes will also be reviewed. Summary: Mechanisms of disease continue to be defined in HPS, providing potential targets for pharmacologic intervention. Outcomes after liver transplantation are also becoming clearer, including the management of HPS with severe hypoxemia.

KW - hepatopulmonary syndrome

KW - hypoxemia

KW - intrapulmonary vasodilatation

KW - liver transplantation

KW - portal hypertension

UR - http://www.scopus.com/inward/record.url?scp=84898543854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898543854&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000067

DO - 10.1097/MOG.0000000000000067

M3 - Review article

C2 - 24686436

AN - SCOPUS:84898543854

SN - 0267-1379

VL - 30

SP - 260

EP - 264

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

IS - 3

ER -

Hepatopulmonary syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this